Overview

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of the bortezomib, lenalidomide and dexamethasone combination in patients with newly diagnosed multiple myeloma. We are looking for the highest dose of the combination that can be given safely and see how well it works as a combination in newly diagnosed patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Celgene Corporation
Massachusetts General Hospital
Millennium Pharmaceuticals, Inc.

Treatments:

BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide